Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
तुलना करने के लिए मीट्रिक्स | SERA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत औद्योगिक | संबंध संबंधSERAपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −4.1x | −3.5x | −0.6x | |
PEG अनुपात | −0.17 | 0.04 | 0.00 | |
क़ीमत/बुक | 1.6x | 1.7x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 1,397.5x | 16.7x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | 40.8% | 31.2% | 40.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 0.7% | 4.4% | अनलॉक करें |